Compare Neurocrine Biosciences Inc (NBIX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while YieldMax Universe Fund of Option Income ETFs trades at $7.55. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| NBIX | YMAX | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $13.14 |
52-Week Low | $123.10 | $7.27 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
YMAX trades at $7.70 with a slight 0.13% daily gain, showing modest positive momentum. The technical outlook is bullish with moving averages supporting upward movement, though oscillators remain neutral. Recent news highlights the fund's weekly dividend distributions but also raises concerns about NAV erosion and sustainability of the high-yield strategy. The fund's structure as a fund-of-funds adds layers of costs that impact overall returns.
YMAX faces significant challenges with declining share price despite high distributions, suggesting the current yield may be unsustainable. The fund's principal erosion and structural cost issues present substantial risks for income-focused investors. While technical indicators show short-term bullish signals, fundamental concerns about the distribution policy and NAV performance warrant cautious consideration for long-term investment viability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
